<h1>GST rate reduction: pharmaceutical and medical device makers must pass benefits to consumers and revise MRPs.</h1> The NPPA directed manufacturers, marketing companies and medical device makers to pass on the benefit of a GST rate reduction to consumers effective September 22, 2025, requiring revision of MRPs and issuance of revised or supplementary price lists to dealers, retailers, state drug controllers and the government. Companies must sensitise dealers, retailers and consumers via electronic, print and social media, and industry associations are encouraged to advertise to ensure compliance. Recalling or relabelling existing stocks is not mandatory if price compliance at retailer level can be ensured.